Evrysdi May Be Available in Early 2022 to Eligible Patients in UK

Evrysdi May Be Available in Early 2022 to Eligible Patients in UK

312921

Evrysdi May Be Available in Early 2022 to Eligible Patients in UK

The National Institute for Health and Care Excellence (NICE) has recommended that Roche’s Evrysdi (risdiplam) be covered by England’s national health service (NHS) and provided at low or no cost to eligible spinal muscular atrophy (SMA) patients as part of a managed access agreement. The current recommendation and its eligibility criteria are consistent with Evrysdi’s approval in the U.K. in May for patients, 2 months and older, with a clinical diagnosis of SMA type 1,…

You must be logged in to read/download the full post.